IP Library Granted Patent US 7,608,256
Granted Patent B2
US 7,608,256 · App. 11/854,027 · Granted Oct 27, 2009

Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type I interferon response

Assignee: Aeras Global TB Vaccine Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,256
App. No.
11/854,027
Granted
Oct 27, 2009
Kind
B2
Abstract

Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.

Claims (19)

1. A genetically engineered bacterium, comprising

nucleic acid sequences encoding

one or more passenger genes; and

one or more factors that inhibit a mammalian type I interferon response,

wherein

said nucleic acid sequences encoding said one or more passenger genes and said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to at least one eukaryotic promoter; or

said nucleic acid sequences encoding said one or more passenger genes are operably linked to a eukaryotic promoter and said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a prokaryotic promoter.

2. The genetically engineered bacterium of claim 1 , wherein said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a eukaryotic promoter.

3. The genetically engineered bacterium of claim 1 , wherein said nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are operably linked to a prokaryotic promoter.

4. The genetically engineered bacterium of claim 1 , wherein nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response are present on a chromosome of said genetically engineered bacterium.

5. The genetically engineered bacterium of claim 1 , wherein one or both of:

i) nucleic acid sequences encoding said one or more passenger genes, and

ii) nucleic acid sequences encoding said one or more factors that inhibit a mammalian type I interferon response,

are present on a plasmid.

6. The genetically engineered bacterium of claim 1 , wherein said one or more factors that inhibit a type I mammalian interferon response are of viral origin.

7. The genetically engineered bacterium of claim 1 , wherein said one or more passenger genes encode tuberculosis antigens.

8. The genetically engineered bacterium of claim 1 , wherein said genetically engineered bacterium is a Shigella bacterium.

9. The genetically engineered bacterium of claim 1 , wherein said genetically engineered bacterium is a Mycobacterium.

10. The genetically engineered bacterium of claim 1 , wherein said one or more passenger genes is a heterologous transgene.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: AERAS
To: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Reel/Frame 047218/0774 →
CHANGE OF NAME Recorded Dec 27, 2016
From: AERAS GLOBAL TB VACCINE FOUNDATION
To: AERAS
Reel/Frame 041303/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2008
From: SADOFF, JERALD C.; JAMILUDDIN, MOHAMAD F.; ANANTHA, RAVI P.; FULKERSON, JR., JOHN F.
To: AERAS GLOBAL TB VACCINE FOUNDATION
Reel/Frame 021099/0161 →
Continuity (1)
Related Publication 20090068222A1 · Mar 12, 2009